KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Change in Intangibles (2020 - 2024)

Recursion Pharmaceuticals (RXRX) has disclosed Change in Intangibles for 3 consecutive years, with $350000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Change in Intangibles changed 0.0% year-over-year to $350000.0, compared with a TTM value of $350000.0 through Dec 2025, down 89.55%, and an annual FY2025 reading of $2.2 million, down 35.58% over the prior year.
  • Change in Intangibles was $350000.0 for Q4 2024 at Recursion Pharmaceuticals, down from $3.0 million in the prior quarter.
  • Across five years, Change in Intangibles topped out at $3.0 million in Q2 2024 and bottomed at $82000.0 in Q3 2023.
  • Average Change in Intangibles over 3 years is $707833.3, with a median of $325000.0 recorded in 2022.
  • The sharpest move saw Change in Intangibles crashed 72.67% in 2023, then changed 0.0% in 2024.
  • Year by year, Change in Intangibles stood at $300000.0 in 2022, then increased by 16.67% to $350000.0 in 2023, then changed by 0.0% to $350000.0 in 2024.
  • Business Quant data shows Change in Intangibles for RXRX at $350000.0 in Q4 2024, $3.0 million in Q2 2024, and $350000.0 in Q4 2023.